Brief: Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
07/05/2024 14:15
May 7 (Reuters) - Precision BioSciences Inc DTIL.O :
* PRECISION BIOSCIENCES ANNOUNCES RECEIPT OF FDA FAST TRACK
DESIGNATION FOR ECUR-506, IECURE’S PROGRAM FOR THE TREATMENT OF
NEONATAL ONSET ORNITHINE TRANSCARBAMYLASE (OTC) DEFICIENCY
Source text for Eikon: ID:nBwVswQma
Further company coverage: DTIL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Precision Biosciences
See all newsPrecision BioSciences Inc reports results for the quarter ended June 30 - Earnings Summary
Precision BioSciences Q2 net loss widens on warrant liability charge
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Brief: Precision Biosciences - Enters First Amendment To Loan And Security Agreement With Banc Of California - SEC Filing